marked.bio

Company

Cogent Biosciences

3 active trials that select patients by a biomarker on marked.bio, across 3 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Upcoming readouts

Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.

Trials

3 of 3 trials shown

  1. A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

    Active, not recruiting Phase 1/2 Cogent Biosciences Started 2025Primary completion 2027-03 NCT06777316

    CGT4859

    …cally advanced, metastatic, and/or unresectable iCCA or other solid tumor with documented FGFR2/3 alteration in blood and/or tumor.

    FGFR3 alteration (mutation or fusion)FGFR2 fusion or rearrangementIntrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult, FGFR2 Gene Fusion/Rearrangement

  2. A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

    Recruiting Phase 1 Cogent Biosciences Started 2026Primary completion 2029-07 NCT07383506

    CGT6297

    Histologically confirmed advanced solid tumor harboring oncogenic PIK3CA mutations in blood and/or tumor:

    PIK3CA activating mutationPIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer

  3. A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

    Recruiting Phase 1 Cogent Biosciences Started 2025Primary completion 2028-05 NCT07361562

    CGT4255

    Part B: Locally advanced, metastatic, and/or unresectable NSCLC with documented ERBB2 mutation in blood and/or tumor

    HER2 (ERBB2) activating mutationNRG1 fusionAdvanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression